Early-stage biotechs now tying CEO pay packages to capital raises

A tighter venture capital market has affected more than the funding biotechs receive. It’s also changed how early-stage companies structure CEO pay packages, according to Leslie Loveless, CEO and managing partner of Slone Partners, a life sciences and healthcare executive search firm. Because of how funding dipped, she told BioSpace, early-stage biotechs started tying CEO salary increases, annual bonuses, equity topoffs and severance package adjustments to raising capital.